Evidence map›Paper›PMID 29089050›Full record

Trial reportParasites & vectors2017

Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe.

Daniela Cavalleri, Martin Murphy, Regina Lizundia Gorbea, Wolfgang Seewald, Jason Drake, Steve Nanchen

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Efficacy of lotilaner (CredelioParasites & vectors · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Management Options forInternational journal of environmental research and public health · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniela CavalleriElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Martin MurphyElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Regina Lizundia GorbeaElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Wolfgang SeewaldElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Jason DrakeElanco Animal Health, 2500 Innovation Way, Greenfield, Indiana, 46140, USA. drake_jon_j@elanco.com.ORCID http://orcid.org/0000-0001-6203-0852
Steve NanchenElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Elanco (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a continuing need for novel approaches to tick control in dogs. One such approach lies in the ability of lotilaner (Credelio™), an isoxazoline with a rapid onset of action, to provide sustained efficacy against ticks. Two studies were undertaken to confirm lotilaner's efficacy, at the minimum dose rate of 20 mg/kg, against the three most common tick species in Europe.

methodsIn each of two studies, 16 Beagle dogs, at least 6 months old, were ranked and blocked by tick counts from infestations placed approximately 1 week before treatment. Within blocks, dogs were randomized to receive either lotilaner flavoured chewable tablets at as close as possible to, but not less than the minimum dose rate of 20 mg/kg, or to be sham-treated controls. Study 1 assessed lotilaner efficacy against concurrent infestations with 50 (± 6) Rhipicephalus sanguineus and 70 (± 6) Ixodes ricinus; Study 2 infestations were with 50 (± 2) Dermacentor reticulatus. Infestations were performed on Day -2 with counts on Day 2, 48 (± 2) hours post-treatment. Post-treatment infestations were performed on Days 7, 14, 21, 28 and 35, and ticks were counted 48 (±2) hours post-infestations. Efficacy was determined by the percent reduction in mean live tick counts.

resultsControl group infestations for each tick species were adequate for assessing lotilaner efficacy at all assessment times. On Day 2 no live ticks were found on any lotilaner-treated dog. For subsequent counts, in Study 1 lotilaner was 100% effective in eliminating live I. ricinus and R. sanguineus on all but two occasions for each tick; on each of those occasions efficacy was sustained at greater than 98.0%. In Study 2, except for a single unattached live tick found on Day 16, efficacy against D. reticulatus was 100% at every post-treatment assessment.

conclusionThe high and sustained efficacy against the three common species of ticks in Europe, R. sanguineus, I. ricinus and D. reticulatus, demonstrates that lotilaner can be a valuable tool in the treatment of canine tick infestations. Lotilaner flavoured chewable tablets were well tolerated and effectiveness was sustained through at least 35 days.

Indexed as

AcaricidesAnimalsDermacentorDog DiseasesDogsEuropeFemaleIxodesMaleRhipicephalus sanguineusTick ControlTick InfestationsTicksTime FactorsAcaricidesCredelioDermacentorDogIxodesLotilanerRhipicephalusTicks

Identifiers

PMID29089050
PMCPMC5664927
OpenAlexW2765668609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.